ArticleBritish journal of cancer2013

Comment on 'Endocrine therapy in prostate cancer: time for re-appraisal of risks, benefits and cost-effectiveness?'.

S I A Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.